Group items tagged

Welcome to Manuscriptedit.com, your online partner for English language editing, proofreading, medical writing, formatting, design & development and publication support services. We offer a comprehensive manuscript editing service before its submission for publication as well as after acceptance by the peer review process.

Researchers investigating the role of cannabis in cancer therapy reveal it has the potential to destroy leukaemia cells, in a paper published in the March 2006 edition of Letters in Drug Design & Discovery.  Led by Dr Wai Man Liu, at Barts and the London, Queen Mary's School of Medicine and Dentistry, the team has followed up on their findings of 2005 which showed that the main active ingredient in cannabis, tetrahydrocannabinol, or THC, has the potential to be used effectively against some forms of cancer.  Dr Liu has since moved to the Institute of Cancer in Sutton where he continues his work into investigating the potential therapeutic benefit of new anti-cancer agents.

"The clinical potential for a liver-protective supplement in cancer care is significant, as I've observed in many years of integrative medical practice," writes Dr. Keith Block, ICT editor. "Several chemotherapy drugs, as well as many of the other drugs cancer patients take, have extremely problematic liver toxicities. With this exclusive edition, the scientific community will have a resource to guide and inspire further research on this very interesting herbal medicine."

A ground-breaking Canada-wide clinical trial led by Dr. Katherine Borden, at the Institute for Research in Immunology and Cancer (IRIC) of the Universit de Montral, has shown that a common anti-viral drug, ribavirin, can be beneficial in the treatment of cancer patients. Published in the journal Blood (First Edition), the study demonstrates that ribavirin suppresses the activities of the eIF4E gene in patients. This gene is dysregulated in 30 percent of cancers including breast, prostate, head and neck, colon and stomach cancer.

Phase I trial of Seneca Valley Virus (NTX-010), a newly discovered systemically deliverable oncolytic picornavirus, in patients with solid tumors with neuroendocrine features. C. M. Rudin, D. Lansey, K. D. Burroughs, L. M. Hales, J. R. Neefe, P. S. Reddy and P. L. Hallenbeck Johns Hopkins Univ, Baltimore, MD; Neotropix, Inc., Malvern, PA. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 18014 © 2007 American Society of Clinical Oncology. Conclusions: NTX-010 is a novel first-in-class anticancer virus with selective tropism for tumors with neuroendocrine features. This is the first anticancer virus given intravenously with documented selective intratumoral infection and replication. Administration was well tolerated. Safety data and viral kinetics will be presented.

Attached please find the final draft of Dr. Kenyon's non-controlled observational study on the use of Coriolus versicolor (non-extracted) in 30 solid tumour cancer patients. The final report will be published in the February edition of Mycology News 7. The patients were Stage III and Stage IV patients in which chemotherapy and radiotherapy were not considered successful. Below please find a synopsis of patient type.